Veklury(Remdesivir)
GILD
Medicare prescription drug cost, prescriptions and prescribers, 2024 · made by Gilead Sciences, Inc.
$381K
Medicare cost, 2024
$381K
Medicare cost, 2024
Medicare drug plans spent $381,126 on Veklury (remdesivir) in 2024, for 292 prescriptions and refills filled by 164 patients. It was first approved in 2020. Spending fell 34% from 2023 to 2024. New York accounts for the most spending ($99,497, 26% of the total).
Medicare cost, 2024
$381K
-34.3% from 2023
Prescriptions
292
$1,305.22 per claim
Patients
164
117 prescribers
Total spending, 2024
$381K
$2,323.94 per patient
Questions and answers
How much does Medicare spend on Veklury?
Medicare prescription drug plans paid $381K for Veklury in 2024, for 292 prescriptions and refills to 164 patients (down 34.3% from 2023). The average cost per claim was $1,305.22.
Which state spends the most on Veklury?
New York had the highest Medicare cost for Veklury in 2024: $99K for 78 claims, followed by Oregon ($39K).
Who prescribes Veklury the most?
Gabriela Rosas-Garcia, internal medicine in Bronx, NY, had the highest Medicare cost for Veklury in 2024: 15 claims costing $14K.
Who makes Veklury?
Veklury is made by Gilead Sciences, Inc. (GILD), listed in the Medicare spending data as Gilead Sciences.
Spending over the years
Medicare spending by year
All plans and makers
Prescriber data: cost by year
Medicare spending on Veklury was $381K in 2024, after a high of $583K in 2023.
By state
Where the prescribers practice, 2024
Medicare cost by state
States with the highest cost
Top prescribers of Veklury, 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| Gabriela Rosas-Garcia Bronx, NY | Internal Medicine | 15 | Under 11 | $14K |
Prescriber data by year
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 56 | 202 | 129 | $254K |
| 2023 | 129 | 444 | 262 | $580K |
| 2024 | 117 | 292 | 164 | $381K |
Makers, 2024
Spending by manufacturer as listed in the spending data
| Manufacturer | Claims | Spending |
|---|---|---|
| Gilead Sciences | 292 | $381K |
Medicaid spending by quarter
Amount reimbursed by state Medicaid programs, all states
Amount reimbursed
Codes
- National drug codes (packages)
- 1
- RxNorm concept IDs
- 2284960, 2367758, 2395502, 2395504
- Application numbers
- NDA214787
More drugs: Medicare drug spending and the Prescriptions view.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
Through September 2026, 13,295 side-effect reports named remdesivir, the active ingredient of Veklury (reports from 2018 on). 11,170 of them (84.0%) were serious, 3,305 named a death and 4,528 named a hospital stay. The reactions named most often were off label use, alanine aminotransferase increased and COVID-19. 5,952 reports came in the last 5 years (since 2022).
How to read these numbers
- A report shows that a patient, doctor or drug company suspected a link. It does not prove that the drug caused the effect.
- Counts are not risk rates. They depend on how many people use the drug, how long it has been sold, news and reporting habits, so they do not show which drug is safer.
- The newest months are partial: reports keep arriving late.
Reports, all years
13,295
536 in 2025 (-47.0% from 2024)
Serious
84.0%
11,170 reports
Deaths named
3,305
24.9% of reports
Hospital stays
4,528
34.1% of reports
Reports by year
Serious reports include those that name a death, a hospital stay, a disability or another serious outcome.
Reports received by year
2026 is the year so far.
Reports naming a death or a hospital stay
One report can name both
Reactions
Reactions named most often
All years. Share = part of all reports in that period. A report can name several reactions.
Patients
As given in the reports; many reports leave sex or age out.
Sex of the patient
All years
Age of the patient
Age when the effect started, all years
Questions and answers
How many side-effect reports name Veklury?
13,295 reports from 2018 through September 2026 named remdesivir, the active ingredient of Veklury. 11,170 of them (84.0%) were serious, 3,305 named a death and 4,528 named a hospital stay.
What are the most reported side effects of Veklury?
2,245 reports named off label use, the reaction named most often, followed by alanine aminotransferase increased (935) and COVID-19 (919). In the last 5 years the reaction named most often was off label use (1,482 reports). A report can name several reactions.
How many side-effect reports named Veklury in 2025?
536 reports were received in 2025 (-47.0% from 2024). 2026 so far: 160 reports through September 2026, and more keep arriving late.
Do side-effect reports prove that Veklury caused a problem?
No. A report shows that a patient, doctor or drug company suspected a link; it does not prove that Veklury caused the effect. Report counts depend on how widely a drug is used, how long it has been sold, news and reporting habits, so they are not risk rates and do not show which drug is safer.
Related pages
- Makers on the stock market:
GILD·GILD drug pipeline - Drug approvals (1 approval on file for remdesivir) · Clinical trials · Medicare drug spending
Side-effect reports from official public data, counted per active ingredient (remdesivir) by the year the report was received, so the brand and generic pages of one ingredient show the same reports. A report can name several drugs and several reactions and counts for each. Reaction names are the standard medical terms used in the reports. Reports whose product could not be matched to a drug are not counted. Updated November 2026.